Klingman & Associates LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Klingman & Associates LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 300.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,137 shares of the medical research company’s stock after buying an additional 2,353 shares during the period. Klingman & Associates LLC’s holdings in Thermo Fisher Scientific were worth $1,940,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Verdence Capital Advisors LLC increased its stake in Thermo Fisher Scientific by 4.5% in the third quarter. Verdence Capital Advisors LLC now owns 4,047 shares of the medical research company’s stock valued at $2,503,000 after purchasing an additional 174 shares during the period. Markel Group Inc. raised its stake in Thermo Fisher Scientific by 20.4% during the 3rd quarter. Markel Group Inc. now owns 35,400 shares of the medical research company’s stock valued at $21,897,000 after acquiring an additional 6,000 shares during the last quarter. Pegasus Partners Ltd. grew its stake in shares of Thermo Fisher Scientific by 29.3% in the 3rd quarter. Pegasus Partners Ltd. now owns 1,005 shares of the medical research company’s stock valued at $622,000 after purchasing an additional 228 shares during the last quarter. Rovin Capital UT ADV raised its stake in shares of Thermo Fisher Scientific by 6.2% during the third quarter. Rovin Capital UT ADV now owns 668 shares of the medical research company’s stock worth $413,000 after purchasing an additional 39 shares during the last quarter. Finally, Washington Trust Advisors Inc. grew its position in Thermo Fisher Scientific by 6.3% in the 3rd quarter. Washington Trust Advisors Inc. now owns 1,286 shares of the medical research company’s stock valued at $795,000 after buying an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Bank of America raised their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, Stephens began coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,150 shares of company stock worth $15,676,125. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO opened at $551.74 on Friday. The business has a fifty day simple moving average of $593.95 and a 200-day simple moving average of $583.63. The firm has a market cap of $211.04 billion, a PE ratio of 34.59, a P/E/G ratio of 3.70 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a fifty-two week low of $437.26 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned $5.69 earnings per share. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.